BioVie, Inc. (BIVI)
Total Valuation
BioVie has a market cap or net worth of $64.21 million. The enterprise value is $51.45 million.
| Market Cap | 64.21M |
| Enterprise Value | 51.45M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
BioVie has 24.98 million shares outstanding. The number of shares has increased by 79.48% in one year.
| Shares Outstanding | 24.98M |
| Shares Change (YoY) | +79.48% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 79.74% |
| Owned by Institutions (%) | 6.28% |
| Float | 5.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 6.45 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.74, with a Debt / Equity ratio of 1.18.
| Current Ratio | 5.74 |
| Quick Ratio | 5.68 |
| Debt / Equity | 1.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -1,165.80%, which is considered low. The company has a ROIC of -4,671.60%.
| Return on Equity (ROE) | -1,165.80% |
| Return on Assets (ROA) | -694.80% |
| Return on Capital (ROIC) | -4,671.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$24.92M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.54% in the last 52 weeks. The beta is 2.26, so BioVie's price volatility has been higher than the market average.
| Beta (1Y) | 2.26 |
| 52-Week Price Change | -82.54% |
| 50-Day Moving Average | 3.51 |
| 200-Day Moving Average | 4.18 |
| Average Volume (30 Days) | 38,431 |
Short Selling Information
The latest short interest is 121,731, so 0.49% of the outstanding shares have been sold short.
| Short Interest | 121,731 |
| Short % of Shares Out | 0.49% |
| Short % of Float | 2.37% |
| Short Ratio (days to cover) | 2.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -149.56M |
| Net Income | -149.53M |
| EBITDA | -148.06M |
| EBIT | -148.29M |
| Earnings Per Share (EPS) | -$6.69 |
Balance Sheet
The company has $24.51 million in cash and $11.75 million in debt, giving a net cash position of $12.75 million or $0.51 per share.
| Cash & Cash Equivalents | 24.51M |
| Total Debt | 11.75M |
| Net Cash | 12.75M |
| Net Cash Per Share | $0.51 |
| Book Value | 9.95M |
| Book Value Per Share | 0.40 |
| Working Capital | 20.47M |
Cash Flow
| Operating Cash Flow | -20.13M |
| Capital Expenditures | n/a |
| Free Cash Flow | -20.13M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioVie does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -232.88% |
| FCF Yield | -31.36% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -79.48% |
| Shareholder Yield | -79.48% |
Analyst Forecast
The average price target for BioVie is $13.94, which is 442.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.94 |
| Price Target Difference | 442.41% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on November 22, 2019. It was a reverse split with a ratio of 1:125.
| Last Split Date | Nov 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:125 |